Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
RPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.05 - $38.00
Previous CloseN/A
Volume726.99K
Average Volume (3M)3.11M
Market Cap
$21.52B
Enterprise Value$30.79B
Total Cash (Recent Filing)$1.49B
Total Debt (Recent Filing)$8.00B
Price to Earnings (P/E)16.1
Beta0.28
Next Earnings
Nov 05, 2025EPS Estimate
1.05Last Dividend Ex-Date
Aug 15, 2025Dividend Yield2.41%
Share Statistics
EPS (TTM)1.14
Shares Outstanding432,293,060
10 Day Avg. Volume3,370,162
30 Day Avg. Volume3,108,043
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue13.36
Enterprise Value/Gross Profit13.36
Enterprise Value/Ebitda15.95
Forecast
1Y Price Target
$43.60Price Target Upside20.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Funding AgreementRPRX announced a funding agreement with ZBIO for up to $300 million for the potential US commercial launch of obexelimab in IgG4-Related Disease.
Royalty Interest AcquisitionRPRX is acquiring a royalty interest in AMGN's Imdelltra for up to $950 million, which includes a significant upfront payment.
Therapy DesignationFDA has granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic PDAC in patients with KRAS G12 mutations.
Bears Say
Market CompetitionAnalyst maintains a Buy rating on Royalty Pharma, citing favorable risk/reward heading into major catalysts, highlighting potential market competition.
Regulatory EnvironmentThe company can adapt to any potential changes in the regulatory environment due to not having an internal 'pipeline'.
Royalty Pharma News
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $24.05 and its highest was $38.00 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $21.52B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Nov 05, 2025 which is in 57 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Aug 06, 2025. The company reported $1.141 earnings per share for the quarter, beating the consensus estimate of $1.032 by $0.109.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 2.41%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.05.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 432,293,060 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.141 in its last earnings report, beating expectations of $1.032. Following the earnings report the stock price went down -2.07%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
Royalty Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.60 (20.88% Upside)
$43.60 (20.88% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 10.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.55%
12-Months-Change
Fundamentals
Return on Equity
15.92%
Trailing 12-Months
Asset Growth
3.77%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma (RPRX) is a leading acquirer of pharmaceutical royalties, focusing on innovative medicines across various therapeutic areas, including oncology, infectious diseases, and neurology. The company specializes in purchasing royalty interests from biopharmaceutical companies and investors, allowing them to monetize their future cash flows from approved drugs. By leveraging its expertise in drug development and commercialization, Royalty Pharma partners with a range of stakeholders in the pharmaceutical industry to maximize the value of their products.
RPRX Company Deck
RPRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights strong financial performance and shareholder returns, a significant collaboration with Revolution Medicines, and positive clinical outcomes, alongside increased guidance and cost efficiencies. However, it also mentions a notable dispute with Vertex and one-time expense impacts.View all RPRX earnings summariesRPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$43.60
▲(20.88% Upside)
Technical Analysis
Ownership Overview
1.85% Insiders
21.37% Mutual Funds
23.72% Other Institutional Investors
36.55% Public Companies and
Individual Investors